TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23121149
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg GEn
Study: 23121149
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg GEn
Study: 23121149
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg GEn
Study: 18462268
Drug: Nonselective β‐blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective β‐blockers
Study: 18462268
Drug: Nonselective β‐blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective β‐blockers (with isosorbide‐5‐mononitrate)
Study: 18462268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nonselective β‐blockers and EBL
Study: 2049361
Drug: Combination sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination sedation technique using nalbuphine and midazolam
Study: 6755207
Drug: Regimens with
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimens with second-line drugs (cytosine arabinoside and asparaginase)
Study: 31651842
Drug: Intravenous dexamethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexamethasone, administered twice daily for 48 hours
Study: 31651842
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice daily for 48 hours
Study: 27633946
Drug: Combined tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined tranexamic acid (IV and topical)
Study: 27633946
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (IV)
Study: 24607889
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment (percutaneous plate via sinus tarsi approach)
Study: 24607889
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (open reduction and internal fixation with conventional plate via L-shaped lateral approach)
Study: 24607889
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment
Study: 14725849
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) with GABAergic mechanisms
Study: 14725849
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) with glutamate reduction mechanisms
Study: 14725849
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs with sustained effects on neuronal mechanisms
Study: 14725849
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs with use-dependent impact on sodium or calcium channels
Study: 14725849
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs with multiple mechanisms of action
Study: 9799053
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg) pre-treatment for 4 days and co-administration with cerivastatin (0.3 mg)
Study: 9799053
Drug: Cerivastatin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.3 mg) alone
Study: 352184
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous injection
Study: 25447301
Drug: 1M sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1M sucrose solution (SU)
Study: 19555360
Drug: 3-month oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month oral function promotion programme including facial muscle and tongue exercises and salivary gland massages
Study: 15692318
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement (400 IU vitamin E, 1 g vitamin C, 90 µg selenium per day)
Study: 11928800
Drug: Systemic chemotherapy‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy‐based regimens
Study: 7522487
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) as part of induction treatment for good-prognosis patients
Study: 7522487
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with interferon (IFN)
Study: 2572145
Drug: Alpidem (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (150 mg/day, 50 mg t.i.d. for 3 weeks)
Study: 4563483
Drug: Cyclobenzaprine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 60 mg/day
Study: 4563483
Drug: Cyclobenzaprine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 150 mg/day
Study: 25747273
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with activated CIK cells (injection of 6.4 × 10(9) autologous CIK cells, 16 times during 60 weeks)
Study: 25747273
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with activated CIK cells
Study: 21114826
Drug: Specialist depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist depression disorder team (psychiatrist and psychotherapist jointly assessing and providing algorithm based drug and psychological treatment)
Study: 21114826
Drug: Usual secondary
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual secondary care treatment
Study: 29907887
Drug: YH4808 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (300 mg) after a single dose at fed state with a standard meal
Study: 29907887
Drug: YH4808 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (300 mg) after a single dose at fed state with a high-fat meal
Study: 29907887
Drug: YH4808 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (100 mg) after multiple dosing for 7 days in fed state with a standard meal
Study: 24435507
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10, 5, 5 mg/kg every 24 h)
Study: 24435507
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (0.20‐0.25 mg/kg every 24 h)
Study: 24435507
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (early postnatal age <8 days)
Study: 24435507
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (early postnatal age <8 days)
Study: 24435507
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (neonates >28 weeks)
Study: 24435507
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (neonates >28 weeks)
Study: 24435507
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (birth weight >1,000 g)
Study: 24435507
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (birth weight >1,000 g)
Study: 7439477
Drug: SADBE (squaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: SADBE (squaric acid dibutylester) applied weekly to one side of the head
Study: 29960684
Drug: High-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiotherapy (RT) at 60 Gy
Study: 17937690
Drug: B221 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: B221 (2 g every 5 hours for 3 days)
Study: 945686
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository control group
Study: 25941220
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g
Study: 25941220
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g
Study: 26080912
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (270 mgI/ml of contrast medium, 80 kVp tube voltage scanning and 50% ASiR)
Study: 26080912
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (350 mgI/ml of contrast medium, 120 kVp routine tube voltage)
Study: 23271695
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bioactive food ingredients (epigallocatechin gallate, capsaicins, piperine, L-carnitine)
Study: 19840309
Drug: Twice-daily pimecrolimus
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily pimecrolimus cream 1%
Study: 19840309
Drug: Once-daily pimecrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily pimecrolimus cream 1%
Study: 15286858
Drug: Creatine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplement (20 g of Creatine monohydrate for 14 days)
Study: 10394855
Drug: Daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of 100 mg for 3 months (fingernail) or 4 months (toenail) - Group A
Study: 10394855
Drug: Intermittent pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pulse therapy with daily doses of 400 mg - Group B
Study: 10394855
Drug: Intermittent pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pulse therapy with daily doses of 300 mg - Group C
Study: 10394855
Drug: Intermittent pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pulse therapy with daily doses of 200 mg - Group D
Study: 10394855
Drug: Further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further treatment with daily doses of 400 mg for non-cured patients
Study: 7117360
Drug: Prednisone (PN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (PN 30 + 30 mg)
Study: 7117360
Drug: Deflazacort (DF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (DF 36 + 36 mg)
Study: 30232528
Drug: GHB 50
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 50 mg/kg orally
Study: 24601887
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of plain 1% 2-chloroprocaine (Group C, n = 66)
Study: 24601887
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of plain 0.5% bupivacaine (Group B, n = 64)
Study: 20015098
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (4.0 mg)
Study: 19537284
Drug: C/BPO HE
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/BPO HE (clindamycin 1%-BPO 5% topical gel with hydrating excipients)
Study: 19537284
Drug: C/BPO (clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/BPO (clindamycin 1%-BPO 5% topical gel without hydrating excipients)
Study: 9882080
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 25 mg (37 mg of the trometamol salt)
Study: 9882080
Drug: Dexketoprofen free
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen free acid 25 mg
Study: 9882080
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 25 mg (repeated dose, twice daily for 7 days)
Study: 2911205
Drug: Daunorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (50 mg/m2, IV) on days 1‐3; cytarabine (Ara‐C) (25 mg/m2, IV) bolus, followed by 160 mg/m2 as a continuous IV infusion daily for 5 days and 6‐thioguanine (6‐TG) (100 mg/m2 po) every 12 hr daily for 5 days (DAT)
Study: 2911205
Drug: Amsacrine (190
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine (190 mg/m2, IV) on days 1‐3 with Ara‐C and 6‐TG at the above doses (AAT)
Study: 2911205
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (alternating cycles of vincristine/methotrexate, cyclophosphamide/6‐TG, daunorubicin/hydroxyurea and Ara‐C/6‐TG)
Study: 9348577
Drug: Cisplatin/5-FU (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/5-FU (group 1): Cisplatin 100 mg/m2 on day 1 followed by continuous infusion of 5-FU 1,000 mg/m2/day on days 2-6, repeated every 21 days for four cycles.
Study: 9348577
Drug: Cisplatin/UFT (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/UFT (group 2): Cisplatin 100 mg/m2 on day 1 followed by oral UFT 300 mg/m2/day on days 2-20, repeated every 21 days for four cycles.
Study: 8396102
Drug: Azithromycin 10
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 10 mg/kg (maximum 500 mg) for three days
Study: 8396102
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V at a dose of 125 mg or 250 mg qid for ten days
Study: 3701861
Drug: Classical conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical conditioning therapy (54 10‐min immersions of both hands in water at 43 degrees C, with whole‐body exposure to cold air at 0 degrees C, three times per day, 3 days per week, for 6 weeks)
Study: 3701861
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (eight sessions of electromyograph feedback while listening to relaxation tapes, followed by 10 sessions of digital thermal feedback while listening to relaxation tapes)
Study: 29066464
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (162 mg weekly)
Study: 27602924
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion (arm A)
Study: 27602924
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion combined with oxaliplatin (arm B)
Study: 27602924
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with 5‐fluorouracil and oxaliplatin without radiation (arm C)
Study: 20811556
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (higher than 300 mg/d)
Study: 20811556
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (300 mg/d)
Study: 20811556
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (duration of therapy)
Study: 20811556
Drug: Successful therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful therapy
Study: 20811556
Drug: Symptom improvement
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom improvement with therapy
Study: 18171211
Drug: Long-term daily
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term daily aspirin use
Study: 16155280
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (E+P) therapy, n = 437
Study: 10539778
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: iron + folate (60 mg and 250 microg, respectively) daily for 3 mo, then folate (250 microg) weekly for 4 mo
Study: 10539778
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: folate daily, and 60 mg iron only once weekly for 3 mo, then weekly iron + folate for 4 mo
Study: 10539778
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: folate daily for 3 mo and then weekly for 4 mo
Study: 10539778
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation over 7 mo (30 doses)
Study: 8690193
Drug: Oral lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral lactulose (20 g)
Study: 8690193
Drug: Intracolonic lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracolonic lactose (20 g)
Study: 8690193
Drug: Intracolonic SCFAs
Normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracolonic SCFAs (54 mmol/180 mL and 90 mmol/180 mL)
Study: 7049781
Drug: Neutral soluble
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral soluble human (semi-synthetic) insulin
Study: 26946343
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) every 8 weeks for 200 weeks
Study: 24513806
Drug: Indomethacin plus
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin plus sublingual nitrate (group A)
Study: 24513806
Drug: Indomethacin plus
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin plus sublingual placebo (group B)
Study: 18440400
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of social support and secure attachment
Study: 16158207
Drug: Detralex 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detralex 500 mg (2 tablets 3 times daily for 5 days after the operation)
Study: 16158207
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Detralex treatment)
Study: 12568734
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg OD of natural conjugated estrogens during 4 months
Study: 1454434
Drug: APDT (Acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: APDT (Acellular Pertussis Vaccine with Lederle Diphtheria and Tetanus Toxoids)
Study: 1454434
Drug: APDT-T/J (Commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: APDT-T/J (Commercially available Japanese Takeda vaccine)
Study: 3931661
Drug: Meptazinol 1
Normalized name: meptazinol 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 1 mg kg‐1
Study: 3931661
Drug: Pethidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.5 mg kg‐1
Study: 30737551
Drug: S-1 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 adjuvant monotherapy
Study: 15818609
Drug: Mental Health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental Health Treatment Court (MHTC)
Study: 9291724
Drug: Cognitive‐Behavioral Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Therapy for Sexually Abused Preschoolers (CBT‐SAP)
Study: 8241988
Drug: i.v. immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. immunoglobulin (1.0 g/kg once weekly for 120 days after transplant) plus CMV‐seronegative blood products
Study: 14668456
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz
Study: 14668456
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz
Study: 14668456
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen containing zidovudine, lamivudine, and efavirenz
Study: 9024266
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human insulin-like growth factor I (rhIGF-I) at 120 micrograms/kg BW twice daily (n = 15)
Study: 9024266
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human insulin-like growth factor I (rhIGF-I) at 80 micrograms/kg BW twice daily (n = 7)
Study: 9024266
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment in idiopathic growth hormone deficiency (GHD) (n = 11)
Study: 3095080
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent mannitol solution
Study: 20356687
Drug: Early salvage
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early salvage hormonal therapy (HT) initiated with PSA < 10 ng/mL
Study: 20356687
Drug: Late salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late salvage hormonal therapy (HT) initiated with PSA ≥ 10 ng/mL
Study: 17942524
Drug: Interferon-beta (IFN-beta)
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta (IFN-beta) treatment
Study: 19742086
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine and 5% prilocaine cream (Emla Astra)
Study: 19742086
Drug: 50% diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% diluted Citanest solution with ring-type infiltration
Study: 15804789
Drug: Swimming (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swimming (water therapy)